A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of cardiometabolic and inflammatory diseases. Our drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator (“SARM”), is being developed as a next generation drug that makes weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass. This activity leads to improved body composition and physical function with expected clinically meaningful incremental weight reduction versus GLP-1 RA monotherapy. Sabizabulin, a microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | 61M | 43M |
| Net Income | -23M | -38M | -93M | -84M | 7.4M | -19M |
| EPS | $-0.52 | $-2.58 | $-6.36 | $-10.50 | $0.90 | $-2.80 |
| Free Cash Flow | -30M | -22M | -89M | -48M | -16M | -2.0M |
| ROIC | -770.4% | -90.2% | -376.5% | -79.7% | 75.1% | -63.0% |
| Gross Margin | - | - | - | - | 78.2% | 72.3% |
| Debt/Equity | 0.00 | 0.87 | 1.54 | 0.63 | 0.17 | 0.71 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -25M | -37M | -94M | -83M | 13M | -15M |
| Operating Margin | 0.0% | - | - | - | 21.2% | -34.6% |
| ROE | -124.0% | -145.4% | -473.4% | -101.5% | 4.9% | -63.0% |
| Shares Outstanding | 16M | 15M | 15M | 8M | 8M | 7M |
VERU INC. passes 2 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 75.3%. At current prices, the estimated annualized return to fair value is -35.8%.
VERU INC. (VERU) has a 5-year average return on invested capital (ROIC) of -39.4%. This is below average and may indicate limited pricing power.
VERU INC. (VERU) has a market capitalization of $38M. It is classified as a small-cap stock.
VERU INC. (VERU) does not currently pay a regular dividend.
VERU INC. (VERU) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
VERU INC. (VERU) generated $-22 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
VERU INC. (VERU) has a debt-to-equity ratio of 0.87. This indicates moderate leverage.
VERU INC. (VERU) reported earnings per share (EPS) of $-2.58 in its most recent fiscal year.
VERU INC. (VERU) has a return on equity (ROE) of -145.4%. A negative ROE may indicate losses or negative equity.
VERU INC. (VERU) has a 5-year average gross margin of 75.3%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 15 years of financial data for VERU INC. (VERU), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
VERU INC. (VERU) has a book value per share of $2.21, based on its most recent annual SEC filing.